CLINICAL TRIAL: STATIN TRIAL

临床试验：他汀类药物试验

• 批准号: 7724991
• 负责人: RUTH MULNARD MCCARGAR
• 金额: $ 0.05万
• 依托单位: UNIVERSITY OF CALIFORNIA, SAN DIEGO
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-12-01 至 2008-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7724991
• 关键词: Activities of Daily Living; Alzheimer' s Disease; Animal Model; Behavioral Symptoms; Cell Culture System; Cholesterol; Class; Clinical; Clinical Trials; Computer Retrieval of Information on Scientific Projects Database; Data; Economics; Epidemiologic Studies; Funding; Grant; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Institution; Laboratories; Laboratory Research; Lipids; Measures; Observational Study; Pathology; Placebos; Quality of life; Recruitment Activity; Research; Research Personnel; Resources; Simvastatin; Source; United States National Institutes of Health; base; cohort; hypercholesterolemia

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. There is compelling evidence from laboratory research in animal model and cell culture systems, observational epidemiological studies, and small clinical trials that lowering cholesterol may reduce the pathology of Alzheimer's disease (AD). This is a clinical trial of simvastatin, a HMG CoA reductase inhibitor, the most commonly used class of lipid lowering agents, to reduce the clinical progression of Alzheimer's disease. The following evidence supports this hypothesis and is the basis for this study. Based on data accrued from observational studies, and that derived in the laboratory, we hypothesize that simvastatin will significantly reduce the clinical progression of AD as measured by the ADAScog. We also hypothesize that those who use simvastatin will show beneficial effects over placebo on measures of activities of daily living, psychiatric and behavioral symptoms, quality of life and economic measures. To study these hypotheses, we propose to recruit a cohort of 400 subjects with AD who do not have hypercholesterolemia.

该子项目是利用该技术的众多研究子项目之一 资源由 NIH/NCRR 资助的中心拨款提供。子项目及 研究者 (PI) 可能已从 NIH 的另一个来源获得主要资金， 因此可以在其他 CRISP 条目中表示。列出的机构是 对于中心来说，它不一定是研究者的机构。 动物模型和细胞培养系统的实验室研究、观察性流行病学研究以及小型临床试验提供了令人信服的证据，表明降低胆固醇可能会减轻阿尔茨海默病 (AD) 的病理。 这是一项辛伐他汀的临床试验，辛伐他汀是一种 HMG CoA 还原酶抑制剂，是最常用的一类降脂药，用于减缓阿尔茨海默病的临床进展。 以下证据支持这一假设，也是本研究的基础。 根据观察性研究和实验室获得的数据，我们假设辛伐他汀将显着减少 AD 的临床进展（如 ADAScog 所测量）。 我们还假设，使用辛伐他汀的患者在日常生活活动、精神和行为症状、生活质量和经济指标方面将显示出优于安慰剂的有益效果。 为了研究这些假设，我们建议招募 400 名没有高胆固醇血症的 AD 受试者组成的队列。